An International, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Controlled Study of the Efficacy and Safety of Sustained-Release Quetiapine Fumarate (Seroquel SR) in the Treatment of Generalized Anxiety Disorder (SILVER)

Trial Profile

An International, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Controlled Study of the Efficacy and Safety of Sustained-Release Quetiapine Fumarate (Seroquel SR) in the Treatment of Generalized Anxiety Disorder (SILVER)

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Feb 2017

At a glance

  • Drugs Paroxetine; Quetiapine
  • Indications Generalised anxiety disorder
  • Focus Registrational; Therapeutic Use
  • Acronyms SILVER
  • Sponsors AstraZeneca
  • Most Recent Events

    • 31 Oct 2012 Planned number of patients changed from 800 to 805 as reported by European Clinical Trials Database record.
    • 06 Dec 2011 Results from a pooled analysis published in the Human Psychopharmacology: Clinical and Experimental.
    • 28 Jun 2009 Planned pooled analysis of data from the GOLD, SILVER and TITANIUM trials presented at the 9th World Congress of Biological Psychiatry.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top